|
|
|
Insider
Information: |
Stahl Neil |
Relationship: |
EVP Research and Devel... |
City: |
|
State: |
|
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
1 |
|
Direct
Shares |
50,999 |
|
Indirect Shares
|
10,439 |
|
|
Direct
Value |
$49,464,440 |
|
|
Indirect Value
|
$10,124,890 |
|
|
Total
Shares |
61,438 |
|
|
Total
Value |
$59,589,331 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
5
|
Stock
price went up :
|
0
|
4
|
Stock
price went down : |
0
|
1
|
|
|
|
Gain/Loss Ratio : |
0.0
|
4.0
|
Percentage
Gain/Loss : |
0.0%
|
57.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Regeneron Pharmaceuticals Inc |
REGN |
EVP Research and Devel... |
2024-02-26 |
50,999 |
2024-02-26 |
10,439 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
140 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 5 of 6
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
|
2020-04-13 |
4 |
D |
$511.56 |
$3,878,648 |
D/D |
(7,582) |
16,877 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
|
2014-08-11 |
4 |
S |
$339.33 |
$3,959,204 |
D/D |
(11,646) |
13,527 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
|
2017-06-15 |
4 |
AS |
$462.72 |
$4,013,177 |
D/D |
(8,567) |
23,950 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
|
2012-02-13 |
4 |
D |
$113.35 |
$4,019,844 |
D/D |
(35,464) |
90,323 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
|
2020-05-08 |
4 |
D |
$560.67 |
$4,034,021 |
D/D |
(7,195) |
16,685 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
|
2020-02-13 |
4 |
AS |
$399.80 |
$4,117,958 |
D/D |
(10,278) |
11,380 |
0 |
% |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Res and Devel Sciences |
|
2012-11-21 |
4 |
S |
$173.80 |
$4,245,442 |
D/D |
(24,357) |
59,121 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
|
2017-06-22 |
4 |
AS |
$521.70 |
$4,423,332 |
D/D |
(8,306) |
23,950 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
|
2018-05-23 |
4 |
D |
$293.68 |
$4,501,821 |
D/D |
(15,329) |
43,380 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Res & Dev Sciences |
|
2012-06-19 |
4 |
AS |
$115.60 |
$4,514,593 |
D/D |
(38,911) |
59,121 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
|
2014-11-18 |
4 |
D |
$406.93 |
$4,659,349 |
D/D |
(11,450) |
18,834 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
|
2020-02-27 |
4 |
AS |
$435.93 |
$4,680,460 |
D/D |
(10,349) |
11,380 |
0 |
% |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Res and Devel Sciences |
|
2012-11-20 |
4 |
D |
$167.17 |
$5,039,005 |
D/D |
(30,143) |
83,478 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
|
2017-06-14 |
4 |
D |
$475.56 |
$5,577,368 |
D/D |
(11,728) |
32,517 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
|
2020-02-12 |
4 |
D |
$402.34 |
$5,923,249 |
D/D |
(14,722) |
21,658 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
|
2017-06-21 |
4 |
D |
$510.02 |
$5,964,174 |
D/D |
(11,694) |
32,256 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
|
2013-05-13 |
4 |
S |
$276.71 |
$6,378,806 |
D/D |
(23,038) |
48,988 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Res & Dev Sciences |
|
2012-06-18 |
4 |
D |
$115.29 |
$6,475,609 |
D/D |
(56,168) |
98,032 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
|
2020-02-26 |
4 |
D |
$451.89 |
$6,620,640 |
D/D |
(14,651) |
21,729 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
|
2014-08-06 |
4 |
D |
$336.11 |
$6,894,624 |
D/D |
(20,513) |
28,014 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
|
2014-02-13 |
4 |
S |
$316.55 |
$7,209,136 |
D/D |
(22,612) |
24,391 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
|
2024-02-07 |
4 |
S |
$947.34 |
$7,637,954 |
D/D |
(8,037) |
52,019 |
0 |
% |
|
REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
|
2021-05-14 |
4 |
OE |
$52.03 |
$7,815,575 |
D/D |
52,500 |
49,005 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
|
2013-05-10 |
4 |
D |
$268.40 |
$8,696,160 |
D/D |
(32,400) |
72,026 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
|
2021-05-17 |
4 |
S |
$518.63 |
$9,101,460 |
D/D |
(17,521) |
24,280 |
0 |
% |
|
140 Records found
|
|
Page 5 of 6 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|